Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
38 hedge funds and large institutions have $172M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
92% more capital invested
Capital invested by funds: $89.5M → $172M (+$82.4M)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
23% more funds holding
Funds holding: 31 → 38 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$22.4M |
| 2 |
DM
Deerfield Management
New York
|
+$11.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$10.9M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$6.3M |
| 2 |
O
OrbiMed
New York
|
-$402K |
| 3 |
Renaissance Technologies
New York
|
-$74K |
| 4 |
LSA
Leonteq Securities AG
Zurich,
Switzerland
|
-$70.9K |
| 5 |
SCM
Sio Capital Management
New York
|
-$56.7K |
FUSN Hedge Fund Activity: Q1 2023 in Review
38 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q1 2023, worth a combined $172M — up 92% from $89.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new FUSN positions and 4 closed out — a net gain of 7 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $22.4M. The largest seller was Braidwell, exiting entirely with an estimated $6.3M sold.
- 38 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q1 2023, up from 31 in Q4 2022.
- Funds reported $172M of Fusion Pharmaceuticals Inc. Common Shares stock for Q1 2023, up 92% quarter-over-quarter.
- 11 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q1 2023 and 4 closed out, a net change of +7 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q1 2023 was Avidity Partners Management, an estimated $22.4M added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q1 2023 was Braidwell, an estimated $6.3M sold.
Based on aggregated 13F filings for Q1 2023.